Synthesis and application of strawberry-like Fe3O4-Au nanoparticles as CT-MR dual-modality contrast agents in accurate detection of the progressive liver disease

Biomaterials

Volumn 51, Issue , 2015, Pages 194-207

  Zhao, Hui Y ^a   Liu, Sen ^a   He, Jian ^b   Pan, Chao C ^a   Li, Hui ^b   Zhou, Zheng Y ^b   Ding, Yin ^a   Huo, Da ^a   Hu, Yong ^a  

^a NANJING UNIVERSITY   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Computed tomography; Gold nanoparticle; Hepatocellular carcinoma; Iron oxide; Liver cirrhosis; Magnetic resonance imaging

Indexed keywords

BIOCOMPATIBILITY; COMPUTERIZED TOMOGRAPHY; DIAGNOSIS; DISEASES; FLUORESCENCE; FRUITS; IRON OXIDES; MAGNETIC RESONANCE IMAGING; MAGNETITE; MAMMALS; NANOMAGNETICS; NANOPARTICLES; SYNTHESIS (CHEMICAL);

BIOCHEMICAL ANALYSIS; CONTRAST ENHANCEMENT; FLUORESCENCE ASSAY; HEPATOCELLULAR CARCINOMA; HYBRID NANOPARTICLE; LIVER CIRRHOSIS; MAGNETIC RESONANCE GUIDANCES; X-RAY ATTENUATION;

GOLD NANOPARTICLES;

ALANINE AMINOTRANSFERASE; BILIRUBIN; CONTRAST MEDIUM; CREATININE; GOLD NANOPARTICLE; IRON OXIDE GOLD NANOPARTICLE; UNCLASSIFIED DRUG; GOLD; MAGNETITE; METAL NANOPARTICLE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CELL DENSITY; CELL PROLIFERATION; CELL VIABILITY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIAGNOSTIC ACCURACY; DRUG SYNTHESIS; FATTY LIVER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER PARENCHYMA; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHAGOCYTOSIS; PRIORITY JOURNAL; RAT; SURFACE PROPERTY; THROMBOCYTE; TRANSMISSION ELECTRON MICROSCOPY; UREA NITROGEN BLOOD LEVEL; ANIMAL; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; CHEMISTRY; DISEASE COURSE; LIVER TUMOR; MOLECULAR IMAGING; MULTIMODAL IMAGING; PATHOLOGY; RADIOGRAPHY; SYNTHESIS; TUMOR CELL LINE; ULTRASTRUCTURE; WISTAR RAT;

FRAGARIA X ANANASSA; MUS; RATTUS;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CONTRAST MEDIA; DISEASE PROGRESSION; FATTY LIVER; FERROSOFERRIC OXIDE; GOLD; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; METAL NANOPARTICLES; MICE, INBRED BALB C; MOLECULAR IMAGING; MULTIMODAL IMAGING; ORGAN SPECIFICITY; RATS, WISTAR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84924904540     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.02.019     Document Type: Article

References (64)

1. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. NEngl J Med 2008, 4:378-390.
2. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 7:2557-2576.
3. Maataoui A., Qian J., Vossoughi D., Khan M.F., Oppermann E., Bechstein W.O., et al. Transarterial chemoembolization alone and in combination with other therapies: a comparative study in an animal HCC model. Eur Radiol 2005, 1:127-133.
4. Zhong Y., Yan J., Deng M., Hu K., Yao Z., Zou Y., et al. Impaired phosphate and tension homologue deleted on chromosome 10 expression and its prognostic role in radical surgery for hepatocellular carcinoma with family aggregation resulting from hepatitis B and liver cirrhosis. Exp Biol Med 2013, 8:866-873.
5. Wong G.L., Chan H.L., Mak C.W., Lee S.K., Ip Z.M., Lam A.T., et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013, 5:1537-1547.
6. Tarao K., Ohkawa S., Miyagi Y., Morinaga S., Ohshige K., Yamamoto N., et al. Inflammation in background cirrhosis evokes malignant progression in HCC development from HCV-associated liver cirrhosis. Scand J Gastroenterol 2013, 6:729-735.
7. Costantini S., Capone F., Maio P., Guerriero E., Colonna G., Izzo F., et al. Cancer biomarker profiling in patients with chronic hepatitis C virus, liver cirrhosis and hepatocellular carcinoma. Oncol Rep 2013, 6:2163-2168.
8. Xie Y.D., Feng B., Gao Y., Wei L. Characteristics of alcoholic liver disease and predictive factors for mortality of patients with alcoholic cirrhosis. Hepatobiliary Pancreat Dis Int 2013, 6:594-601.
9. Abraldes J.G., Araujo I.K., Turón F., Berzigotti A. Diagnosing and monitoring cirrhosis: liver biopsy, hepatic venous pressure gradient and elastography. Gastroenterol Hepatol 2012, 7:488-495.
10. Al-Muhannadi N., Ansari N., Brahmi U., Satir A.A. Differential diagnosis of malignant epithelial tumours in the liver: an immunohistochemical study on liver biopsy material. Ann Hepatol 2011, 4:508-515.
11. Procopet B., Bureau C., Métivier S., Selves J., Robic M.A., Christol C., et al. Tolerance of liver biopsy in a tertiary care center: comparison of the percutaneous and the transvenous route in 143 prospectively followed patients. Eur J Gastroenterol Hepatol 2012, 10:1209-1213.
12. Mölleken C., Sitek B., Henkel C., Poschmann G., Sipos B., Wiese S., et al. Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology 2009, 4:1257-1266.
13. Polasek M., Fuchs B.C., Uppal R., Schühle D.T., Alford J.K., Loving G.S., et al. Molecular MR imaging of liver fibrosis: a feasibility study using rat and mouse models. JHepatol 2012, 3:549-555.
14. Chung J., Yu J.S., Kim D.J., Chung J.J., Kim J.H., Kim K.W. Hypervascular hepatocellular carcinoma in the cirrhotic liver: diffusion-weighted imaging versus superparamagnetic iron oxide-enhanced MRI. Magn Reson Imaging 2011, 9:1235-1243.
15. Ishigami K., Tajima T., Fujita N., Nishie A., Asayama Y., Kakihara D., et al. Hepatocellular carcinoma with marginal superparamagnetic iron oxide uptake on T2*-weighted magnetic resonance imaging: histopathologic correlation. Eur J Radiol 2011, 3. e293-8.
16. Tanaka M., Nakashima O., Wada Y., Kage M., Kojiro M. Pathomorphological study of Kupffer cells in hepatocellular carcinoma and hyperplastic nodular lesions in the liver. Hepatology 1996, 4:807-812.
17. Dixon L.J., Barnes M., Tang H., Pritchard M.T., Nagy L.E. Kupffer cells in the liver. Compr Physiol 2013, 2:785-797.
18. Goldberg H.I., Moss A.A., Stark D.D., McKerrow J., Engelstad B., Brito A. Hepatic cirrhosis: magnetic resonance imaging. Radiology 1984, 3:737-739.
19. Chou C.T., Chou J.M., Chang T.A., Huang S.F., Chen C.B., Chen Y.L., et al. Differentiation between dysplastic nodule and early-stage hepatocellular carcinoma: the utility of conventional MR imaging. World J Gastroenterol 2013, 19:7433-7439.
20. Haimerl M., Verloh N., Zeman F., Fellner C., Müller-Wille R., Schreyer A.G., et al. Assessment of clinical signs of liver cirrhosis using T1 mapping on Gd-EOB-DTPA-enhanced 3T MRI. PLoS One 2013, 8:856-858.
21. 49 nanoparticles. Biomaterials 2014, 33:9155-9166.
22. Huo D., Ding J., Cui Y.X., Xia L.Y., Li H., He J., et al. X-ray CT and pneumonia inhibition properties of gold-silver nanoparticles for targeting MRSA induced pneumonia. Biomaterials 2014, 33:7032-7041.
23. Ng C.S., Hobbs B.P., Chandler A.G., Anderson E.F., Herron D.H., Charnsangavej C., et al. Metastases to the liver from neuroendocrine tumors: effect of duration of scan acquisition on CT perfusion values. Radiology 2013, 3:758-767.
24. Wen S., Li K., Cai H., Chen Q., Shen M., Huang Y., et al. Multifunctional dendrimer-entrapped gold nanoparticles for dual mode CT/MR imaging applications. Biomaterials 2013, 5:1570-1580.
25. Chen Q., Li K., Wen S., Liu H., Peng C., Cai H., et al. Targeted CT/MR dual mode imaging of tumors using multifunctional dendrimer-entrapped gold nanoparticles. Biomaterials 2013, 21:5200-5209.
26. Wang L., Xing H., Zhang S., Ren Q., Pan L., Zhang K., et al. AGd-doped Mg-Al-LDH/Au nanocomposite for CT/MR bimodal imagings and simultaneous drug delivery. Biomaterials 2013, 13:3390-3401.
27. Chou S.W., Shau Y.H., Wu P.C., Yang Y.S., Shieh D.B., Chen C.C. Invitro and invivo studies of FePt nanoparticles for dual modal CT/MRI molecular imaging. JAm Chem Soc 2010, 38:13270-13278.
28. 4 at Au nanoparticles. JPhys Chem B 2005, 46:21593-21601.
29. 4 dumbbell nanoparticles for sensitive and selective turn-on fluorescent detection of cyanide based on the inner filter effect. Chem Commun 2011, 29:8268-8270.
30. 4 heterostructured nanoparticles for invivo computed tomography and magnetic resonance dual model imaging. Nanoscale 2014, 1:199-202.
31. 4/Ag/Au composites for immunoassay based on surface plasmon resonance biosensor. Colloids Surf B Biointerfaces 2013, 102:165-170.
32. 4 nanoparticles. Nano Lett 2005, 2:379-382.
33. 4 nanoparticles for target-specific platin delivery. JAm Chem Soc 2009, 12:4216-4217.
34. Gu H., Yang Z., Gao J., Chang C.K., Xu B. Heterodimers of nanoparticles: formation at a liquid-liquid interface and particle-specific surface modification by functional molecules. JAm Chem Soc 2005, 1:34-35.
35. Xu C., Tung G.A., Sun S. Size and concentration effect of gold nanoparticles on X-ray attenuation as measured on computed tomography. Chem Mater 2008, 13:4167-4169.
36. Negishi Y., Tsukuda T. One-pot preparation of subnanometer-sized gold clusters via reduction and stabilization by meso-2,3-dimercaptosuccinic acid. JAm Chem Soc 2003, 14:4046-4047.
37. 4 magnetic nanoparticles. Biomaterials 2013, 16:4078-4088.
38. 4 at Au composite nanoparticles for dual-mode MR/CT imaging applications. ACS Appl Mater Interfaces 2013 Oct 23, 20:10357-10366.
39. 4 at C at Ag hybrid nanoparticles as dual modal imaging probes and near-infrared light-responsive drug delivery platform. Biomaterials 2013, 2:571-581.
40. Huang P., Lin J., Wang S., Zhou Z., Li Z., Wang Z., et al. Photosensitizer-conjugated silica-coated gold nanoclusters for fluorescence imaging-guided photodynamic therapy. Biomaterials 2013, 19:4643-4654.
41. (64)Cu-doped chelator-free gold nanoclusters. Biomaterials 2014, 37:9868-9876.
42. Paillard A., Hindré F., Vignes-Colombeix C., Benoit J.P., Garcion E. The importance of endo-lysosomal escape with lipid nanocapsules for drug subcellular bioavailability. Biomaterials 2010, 29:7542-7554.
43. Lammers T., Kühnlein R., Kissel M., Subr V., Etrych T., Pola R., et al. Effect of physicochemical modification on the biodistribution and tumor accumulation of HPMA copolymers. JControl Release 2005, 1:103-118.
44. Schädlich A., Caysa H., Mueller T., Tenambergen F., Rose C., Göpferich A., et al. Tumor accumulation of NIR fluorescent PEG-PLA nanoparticles: impact of particle size and human xenograft tumor model. ACS Nano 2011, 11:8710-8720.
45. Fotiadu A., Gagalis A., Akriviadis E., Kotoula V., Sinakos E., Karkavelas G., et al. Clinicopathological correlations in a series of adult patients with non-alcoholic fatty liver disease. Pathol Int 2010, 2:87-92.
46. Patel S., Kiefer T.L., Ahmed A., Ali Z.A., Tremmel J.A., Lee D.P., et al. Comparison of the frequency of coronary artery disease in alcohol-related versus non-alcohol-related endstage liver disease. Am J Cardiol 2011, 11:1552-1555.
47. Bedossa P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 2014, 2:565-575.
48. Kane A.G., Redwine M.D., Cossi A.F. Characterization of focal fatty change in the liver with a fat-enhanced inversion-recovery sequence. JMagn Reson Imaging 1993, 4:581-586.
49. Qayyum A., Chen D.M., Breiman R.S., Westphalen A.C., Yeh B.M., Jones K.D., et al. Evaluation of diffuse liver steatosis by ultrasound, computed tomography, and magnetic resonance imaging: which modality is best?. Clin Imaging 2009, 2:110-115.
50. Kröncke T.J., Taupitz M., Kivelitz D., Scheer I., Daberkow U., Rudolph B., et al. Multifocal nodular fatty infiltration of the liver mimicking metastatic disease on CT: imaging findings and diagnosis using MR imaging. Eur Radiol 2000, 7:1095-1100.
51. Tsochatzis E.A., Bosch J., Burroughs A.K. Liver cirrhosis. Lancet 2014, 30:1749-1761.
52. Borzio M., Fargion S., Borzio F., Fracanzani A.L., Croce A.M., Stroffolini T., et al. Impact of large regenerative, low grade and high grade dysplastic nodules in hepatocellular carcinoma development. JHepatol 2003, 2:208-214.
53. Kita K., Kita M., Sato M., Ooshima A., Yamada R. MR imaging of liver cirrhosis. Acta Radiol 1996, 2:198-203.
54. Tonan T., Fujimoto K., Qayyum A., Morita Y., Nakashima O., Ono N., et al. CD14 expression and Kupffer cell dysfunction in non-alcoholic steatohepatitis: superparamagnetic iron oxide-magnetic resonance image and pathologic correlation. JGastroenterol Hepatol 2012, 4:789-796.
55. Lee J.G., Kang C.M., Park J.S., Kim K.S., Yoon D.S., Choi J.S., et al. The actual five-year survival rate of hepatocellular carcinoma patients after curative resection. Yonsei Med J 2006, 1:105-112.
56. Kim S.M., Chae M.K., Yim M.S., Jeong I.H., Cho J., Lee C., et al. Hybrid PET/MR imaging of tumors using an oleanolic acid-conjugated nanoparticle. Biomaterials 2013, 33:8114-8121.
57. 4:Eu ultrathin nanosheet for multimodal PET/MR imaging. Biomaterials 2014, 30:8649-8658.
58. (64)Cu-labeled magnetic nanoparticles as a dual-modality PET/MR imaging agent. Bioconjug Chem 2010, 4:715-722.
59. Mitchell N., Kalber T.L., Cooper M.S., Sunassee K., Chalker S.L., Shaw K.P., et al. Incorporation of paramagnetic, fluorescent and PET/SPECT contrast agents into liposomes for multimodal imaging. Biomaterials 2013, 4:1179-1192.
60. Wu Y., Sun Y., Zhu X., Liu Q., Cao T., Peng J., et al. Lanthanide-based nanocrystals as dual-modal probes for SPECT and X-ray CT imaging. Biomaterials 2014, 16:4699-4705.
61. Yan K., Li H., Li P., Zhu H., Shen J., Yi C., et al. Self-assembled magnetic fluorescent polymeric micelles for magnetic resonance and optical imaging. Biomaterials 2014, 1:344-355.
62. Yeh C.S., Su C.H., Ho W.Y., Huang C.C., Chang J.C., Chien Y.H., et al. Tumor targeting and MR imaging with lipophilic cyanine-mediated near-infrared responsive porous Gd silicate nanoparticles. Biomaterials 2013, 22:5677-5688.
63. Wu S.C., Lin K.L., Wang T.P., Tzou S.C., Singh G., Chen M.H., et al. Imaging specificity of MR-optical imaging agents following the masking of surface charge by poly(ethylene glycol). Biomaterials 2013, 16:4118-4127.
64. Cherry S.R. Multimodality invivo imaging systems: twice the power or double the trouble?. Annu Rev Biomed Eng 2006, 8:35-62.